Oppenheimer Assumes Evommune Inc (EVMN) at Outperform

Oppenheimer analyst Kostas Biliouris assumes coverage on Evommune Inc (NYSE: EVMN) with a Outperform rating and a price target of $50.00.

The analyst commented, "Investor focus is on 2Q26 readout in CSU, wherein substantial unmet need remains due to inconvenience (injectables) and/or suboptimal safety/efficacy of the multiple approved options. EVO756 (MRGPRX2-targeted) offers a compelling alternative, combining convenient oral dosing with a differentiated/promising mechanism, targeting mast cells and sensory neurons. Based on available CIndU data, we expect EVO756's PhII readout in 2Q26 to offer Dupixent-like safety with Rhapsido-like or better efficacy (main EVO756 competitor, warning/precaution for bleeding), potentially driving 50– 100% upside in EVMN. Beyond CSU, EVO756 data in atopic dermatitis in 2H26 could help further assess Evommune’s opportunity in this multibillion-dollar market (EVO301 data here)."

For an analyst ratings summary and ratings history on Evommune Inc click here. For more ratings news on Evommune Inc click here.

Shares of Evommune Inc closed at $24.58 yesterday.

You May Also Be Interested In

• SpaceX (SPCX) Added to Morgan Stanley Space 60 List, Qorvo (QRVO) Removed
• Stifel Reiterates Buy Rating on On Holding AG (ONON) as 'Compelled by the Setup'
• Landstar System (LSTR) PT Raised to $186 at Stifel